BioCatalystWatch
PULMWorkspace / PULM / OverviewCompany library
Price
Market cap
Next catalystExpected 2026PUR1900 — Cipla India Phase 3 development plan · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

Partner / License out

PUR1900

PreINDP1P2FilingApproved
Upcoming / outlook

History / paused

PUR1900

PUR1900

PreINDP1P2P3FilingApproved

PreINDP1P3FilingApproved
Upcoming / outlook

PreINDP1P2P3FilingApproved

p38 MAPK × Src kinases × Syk

PreINDP1P2P3FilingApproved
PUR1900

PreINDP1P2P3FilingApproved
PUR1900

PreINDP1P2P3FilingApproved

Kinases (unspecified narrow spectrum)

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

PULM PR & News

PR & News

PULM SEC archive